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1. Introduction 
Secondary hyperparathyroidism (sHPT) represents the adaptive and very often finally 
maladaptive response of the organism to control the disturbed homeostasis of calcium, 
phosphorus and vitamin D metabolism caused by declining renal function. Dysregulation of 
calcium and phosphorus homeostasis leads to elevated levels of the phosphatonin fibroblast 
growth factor 23 (FGF23), decreased renal phosphorus excretion, increased serum 
phosphorus, and diminished synthesis of calcitriol (1,25(OH)2D3), the active form of vitamin 
D. These alterations result in increased secretion and synthesis of parathyroid hormone 
(PTH) and parathyroid cell hyperplasia (Cunningham et al., 2011).  
Evidence is available that these disturbances in mineral metabolism lead to vascular 
(Goodman et al., 2000; Raggi et al., 2002) and valvular (Ribeiro et al., 1998) calcifications and 
are directly linked to an increased risk of cardiovascular morbidity and mortality as well as 
excess all-cause mortality (Covic et al., 2009). In accordance to a recent systematic review, 
the risk of cardiovascular and all-cause mortality is greatest with elevated serum 
phosphorus followed by increased serum calcium and PTH (Covic et al., 2009). Apart from 
extra-skeletal side effects, sHPT also leads to profound alterations in bone metabolism 
which become obvious in the different forms of renal osteodystrophy (Malluche & Faugere, 
1990; Moe et al., 2006). This clinical syndrome encompassing mineral, bone and 
cardiovascular abnormalities has been termed CKD-related Mineral and Bone Disorder 
(CKD-MBD) (Moe et al., 2006). Furthermore, sHPT is thought to play a role in various other 
complications of end-stage renal disease as bone pain, bone fractures, muscle dysfunction, 
sexual dysfunction, disturbed hematopoiesis, immune dysfunction, pruritus and calcific 
uremic arteriolopathy (calciphylaxis) (Rodriguez & Lorenzo, 2009). An overview of the 
current understanding of the pathogenesis of sHPT is given in Figure 1. 
In an attempt to improve clinical care, the National Kidney Foundation’s Kidney Disease 
Outcomes Quality Initiative (NKF-K/DOQITM [KDOQI]) has recommended target ranges 
for serum intact PTH, serum phosphorus and total corrected serum calcium (KDOQI, 2003). 
More recently, the Kidney Disease Improving Global Outcomes (KDIGO) guidelines for 
diagnosis, evaluation, prevention and treatment of CKD-MBD have been published 
(KDIGO, 2009) and endorsed by the US KDOQI (Uhlig et al., 2010) and European Renal Best 
Practice (Goldsmith et al., 2010) groups. These latter guidelines have tried to provide 
evidence-based recommendations, but due to the very limited availability of high quality 
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Fig. 1. Pathogenesis of secondary hyperparathyroidism. Declining kidney function causes 
reduced renal conversion of 25(OH)D to 1,25(OH)2D by CYP27B1 (25(OH)D-1-hydroxylase) 
and elevated serum phosphorus levels due to diminished phosphorus excretion. Increased 
phosphorus concentration, decreased calcium concentration and markedly reduced serum 
calcitriol levels lead to increased PTH synthesis and secretion in the parathyroid glands. 
Elevated FGF23 expression, to counteract the reduced phosphorus excretion, downregulates 
residual renal 25(OH)D-1-hydroxylase, additionally promoting the development of sHPT. 
These metabolic changes are accompanied by a variable downregulation and underexpression 
of the calcium-sensing receptor and vitamin D receptor on parathyroidal cells, rendering the 
parathyroid gland unable to respond appropriately to calcium and calcitriol. Dashed lines 
indicate counter-regulatory pathways. Abbreviations: FGF23, fibroblast growth factor 23; P, 
phosphorus; Ca2+, calcium; CaSR, calcium-sensing receptor; VDR, vitamin D receptor; FGFR1, 
fibroblast growth factor receptor 1, PTG, parathyroid gland. 
clinical interventional trials with skeletal, cardiovascular or mortality end-points in this 
field, fewer and less mandatory recommendations are given compared to the older KDOQI 
guidelines. 
The achievement of these target ranges set by the KDOQI or KDIGO guidelines is quite 
challenging (Young et al., 2004) and failure to reach these targets has been shown to be 
associated with increased risk for death compared to simultaneously achieving the targets 
for all three biochemical parameters PTH, calcium and phosphorus (Danese et al., 2008). 
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The 84-amino-acid peptide hormone PTH has a very short half-life of two to four minutes 
after parathyroid secretion. It is metabolized to shorter fragments in the liver which are then 
excreted by the kidneys. With increasing renal failure and progressive CKD the proportion 
of these fragments with a 5 to 10 times longer half-life raises due to decreased renal 
clearance. Although the exact composition and possible function of the various PTH 
fragments are not yet fully elucidated, experimental data clearly found a clinically relevant 
biological activity of some of these fragments. Routinely used second-generation PTH 
assays, globally called “intact” PTH assays because they were thought to measure the full-
length PTH 1-84 molecule only, recognize with various cross-reactivities (from 
approximately 50 to 100%) a PTH fragment, which co-elutes in high-performance liquid 
chromatography with a synthetic PTH 7–84 fragment. With progressive renal failure the 
amount of this and related PTH fragments gradually increases from about 20% in healthy 
individuals to about 50% in hemodialysis patients (Brossard et al., 2000). Therefore, at least 
in part, the progressive increase in measured PTH with decreasing renal function is also 
linked to the decreased renal metabolism and clearance of PTH 1-84 and its fragments. The 
different commercially available second-generation PTH assays have variable cross-
reactivity with the PTH 7-84 fragment, therefore PTH measurements with different assays 
are not fully comparable and due to lacking standardization of PTH measurement sHPT 
patients might be classified differently according to KDOQI or KDIGO guidelines, resulting 
in different and due to misclassification potentially disadvantageous therapeutic 
interventions (Koller et al., 2004). Newer third-generation PTH assays, which show no cross-
reactivity with the PTH 7-84 and related fragments, have been developed. Unfortunately, in 
all bone biopsy studies, which were later used to establish the KDOQI and KDIGO PTH 
target ranges, the first available second-generation PTH assay was used, but this assay is no 
longer commercially available. In an attempt to provide some kind of comparability of PTH 
measurements and consistent classification, correcting factors for the different second-
generation PTH assays were proposed (Souberbielle et al., 2010). 
Current therapeutic strategies include the modification of calcium and phosphorus balance 
through restricted dietary calcium and phosphorus intake and removal during 
hemodialysis, administration of phosphate binders, vitamin D receptor activators (calcitriol 
and newer vitamin D analogues) and the calcimimetic cinacalcet, and ultimately 
parathyroidectomy in very severe sHPT. These interventions have been shown to improve 
the biochemical parameters (PTH, calcium, phosphorus), bone histology or 
histomorphometry and cardiovascular calcification, but still there is lacking evidence that 
improvements in these surrogate parameters translate into better patient outcomes. 
Traditionally interventions to treat sHPT primarily aimed at bone health, but over the years 
new experimental insights into cardiovascular calcification and epidemiological data about 
associated cardiovascular morbidity and mortality risk switched the emphasis from bone to 
cardiovascular health. 
2. Treatment of hyperphosphatemia 
Declining renal function inevitably causes phosphorus retention due to decreased renal 
phosphorus clearance. This mechanism starts early in chronic kidney disease. However, 
hyperphosphatemia is prevented until the late stages of chronic kidney disease by an 
increase in FGF23 and PTH which control phosphorus homeostasis for a definite time. 
Initially, phosphorus retention stimulates FGF23 and PTH secretion, which in turn suppress 
www.intechopen.com
 
Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice 
 
334 
renal phosphorus reabsorption and increase renal phosphorus excretion. FGF23 also 
suppresses calcitriol (1,25(OH)2D3) production, which diminishes intestinal phosphorus 
absorption but allows increases in PTH levels. Whereas FGF23 suppresses PTH secretion in 
normal parathyroid glands, resistance to its effect occurs with further loss of kidney 
function because of decreased Klotho and FGF receptor 1 expression in the parathyroid 
glands and the kidney. Thus, as chronic kidney disease progresses to late stages, these 
homeostatic mechanisms are inevitably overwhelmed, hyperphosphatemia ensues, and the 
levels of PTH and FGF23 increase progressively (Cunningham et al., 2011). 
Robust observational data show a clear association of higher serum phosphorus levels with 
cardiovascular events and mortality (Block et al., 1998, 2004). The exact threshold above 
which risk significantly increases is not definitely known and varies across the studies from 
5.0 to 7.0 mg/dL (1.6 to 2.3 mmol/L) (Covic et al., 2009). However, it has never been 
determined in randomized placebo-controlled trials whether treating hyperphosphatemia to 
specific target ranges improves clinical patient outcomes. The KDIGO guidelines therefore 
suggest to decrease serum phosphorus levels toward the reference range in patients with 
chronic kidney disease 5D (KDIGO, 2009). 
Therapeutic interventions to treat hyperphosphatemia include restriction of dietary 
phosphorus intake, administration of phosphate binders and increasing the frequency or 
length of dialysis sessions. 
2.1 Dietary phosphorus restriction 
Dietary phosphorus assessment and restriction is the cornerstone of the treatment of 
hyperphosphatemia. Educational support and dietary guidelines should be offered to the 
patients by a skilled dietician. Restriction of dietary phosphorus intake, however, requires a 
reduction in oral protein intake, as protein-rich foods are the main source of dietary 
phosphorus (Shinaberger et al., 2008). Lowering protein intake can lead to malnutrition and 
protein-energy wasting and thereby increasing mortality in dialysis patients (Lacson et al., 
2007). It is very important to avoid concomitant malnutrition by forced dietary protein 
restriction, as protein restriction as means to lower dietary phosphorus intake may 
outweigh the benefit of controlled phosphorus and may lead to greater mortality 
(Shinaberger et al., 2008). One possibility for overcoming the problem of concordant overall 
protein restriction and the risk of malnutrition with reduced dietary phosphorus intake 
would be to avoid phosphorus-rich ingredients that are added to processed foods and 
beverages (Sherman & Mehta, 2009a, 2009b). Contrary to natural sources of organic 
phosphorus, such as meat or dairy products, such phosphorus sources are dissociated from 
protein intake. Reducing the consumption of such phosphorus additives might help to 
decrease phosphorus intake without the risk of protein-energy wasting (Sullivan et al., 
2009). Additionally, the intake of protein sources with low phosphorus to protein ratios 
might further help to limit phosphorus intake (Noori et al., 2010).  Nutritional guidelines 
recommend a maximum of 800 to 1000 mg (25 to 35 mmol) daily dietary phosphorus intake 
(Fouque et al., 2007). Nevertheless, dietary modifications alone are generally not sufficient to 
reduce phosphorus intake sufficiently in most patients, but help to save phosphate binders 
and probably reduce the high pill burden. 
2.2 Phosphate binders 
The use of oral phosphate binders to block intestinal phosphorus absorption has been 
shown to effectively reduce serum phosphorus levels irrespective of the phosphate binder 
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class. Although no placebo-controlled randomized trial has been done so far to prove that 
reduction in serum phosphorus by the use of phosphate binders improves patient outcomes, 
a recent prospective observational study in a large number of incident dialysis patients has 
shown that the use of any phosphate binder (versus none) offers a clear survival benefit 
independent of absolute serum phosphorus concentration and co-medication (Isakova et al., 
2009).  
Available phosphate binders include the calcium salts calcium acetate and calcium 
carbonate, aluminium hydroxide, the polymeric anion-exchange resins sevelamer 
hydrochloride and sevelamer carbonate, lanthanum carbonate and the newer so far not well 
studied compounds ferric citrate, SBR759 (iron-based), magnesium/calcium carbonate and 
magnesium carbonate/calcium acetate. They differ in composition, phosphate-binding 
capacity, form and have specific potential advantages and disadvantages, which are 
summarized in Table 1. 
Considering the different agents there are no data at present to favour one phosphate 
binder, because there is no proven superiority of any phosphate binder or binder class for 
relevant clinical outcomes. According to a recent systematic review and meta-analysis of 
available randomized controlled trials all phosphate binders decrease serum phosphorus 
levels compared with placebo. The newer drugs sevelamer hydrochloride and lanthanum 
carbonate do not result in superior control of biochemical parameters compared with 
calcium salts. In contrast, in head-to-head studies calcium salts enable a greater reduction of 
serum phosphorus than sevelamer hydrochloride. Whereas both calcium salts (calcium 
acetate and carbonate) do not differ with regard to serum calcium levels, sevelamer 
hydrochloride and lanthanum carbonate are associated with significantly lower rates of 
treatment-related hypercalcemia, which may result in decreased cardiovascular calcification. 
However, the finding of slower or less progression of cardiovascular calcification in 
sevelamer-treated patients is inconsistent across the studies. Studies revealed no difference 
in PTH suppression when comparing calcium acetate with calcium carbonate or lanthanum   
 
Binder 
source 
Form Content 
(mineral/me-
tal/element) 
Phosphate-
binding 
capacity 
Daily dose Advantages Disadvantages 
Calcium 
carbonate 
tablet, 
capsule, 
chewable, 
gum, liquid
200 mg 
elemental 
Ca2+  per 500 
mg carbonate 
(40% 
elemental 
Ca2+) 
39 mg 
phosphate 
per 1 
gramm 
calcium 
carbonate 
1500 to 3500 
mg 
(3–7 tablets) 
effective 
phosphate-
binding, 
inexpensive, 
readily 
available, long-
term experience 
potential for 
hypercalcemia and 
hypercalcemia-
associated risks, 
gastrointestinal side 
effects 
Calcium 
acetate 
capsule, 
tablet 
126.7 mg 
elemental 
Ca2+ per 500 
mg tablet, 169 
mg elemental 
Ca2+ per 667 
mg capsule 
(25% 
elemental 
Ca2+)  
45 mg 
phosphate 
per 1 
gramm 
calcium 
acetate 
3000 to 6000 
mg 
 (6 to 12 
tablets) 
 
effective 
phosphate-
binding, 
potentially 
higher binding 
capacity and 
lower Ca2+ 
absorption than 
carbonate, 
inexpensive, 
long-term 
experience 
potential for 
hypercalcemia and 
hypercalcemia-
associated risks, 
gastrointestinal side 
effects, more costly 
than carbonate 
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Aluminium 
hydroxide 
tablet, 
capsule, 
liquid 
Varying with 
100 to 600 mg 
aluminium 
per tablet 
22.3 mg 
phosphate 
per 5 ml,  
18.8 mg 
phosphate 
per 1000 
mg 
600 to 1800 
mg  
(pill burden 
dependent on 
content per 
tablet) 
very effective 
phosphate-
binding capacity
potential for 
aluminium toxicity, 
gastrointestinal side 
effects 
Sevelamer-
HCl 
tablet none 64 mg 
phosphate 
per 800 mg 
sevelamer-
HCl 
2400 to 9600 
mg 
(3 to 12 
tablets) 
effective 
phosphate-
binding 
capacity, no Ca2+ 
and metal 
content, reduces 
LDL- 
cholesterol, 
possible 
potential for 
reduced 
calcification 
costs, potential for 
decrease in 
bicarbonate levels, in 
presence of 
hypocalcemia need 
for Ca2+ supplement, 
higher risk of 
gastrointestinal side 
effects compared to 
Ca2+ salts 
Sevelamer 
carbonate 
tablet, 
powder 
none same as 
sevelamer-
HCl 
2400 to 9600 
mg 
(3 to 12 
tablets, 1 to 4 
packets) 
same as 
sevelamer-HCl, 
but lower risk of 
metabolic 
acidosis 
assumed to have 
same disadvantages 
as sevelamer-HCl 
except decrease in 
bicarbonate levels, 
less well studied 
Lanthanum 
carbonate 
chewable 
tablet 
250, 500, 750 
or 1000 mg 
elemental 
lanthanum 
per tablet 
NA 750 to 3750 
mg 
(3 to 5 
chewable 
tablets) 
effective 
phosphate-
binding 
capacity, no 
Ca2+, chewable, 
reduced pill 
burden 
costs, gastrointestinal 
side effects, potential 
for accumulation 
Magnesium 
carbonate/cal
cium acetate 
tablet 60 mg Mg per 
235 mg 
MgCO3, 110 
mg elemental 
Ca2+ per 435 
mg Ca2+ 
acetate 
NA 705/1305 mg 
to 2820/5220 
mg 
(3 to 12 
tablets) 
effective, 
potential for 
lower Ca2+ load 
than pure Ca2+-
based binders 
potential for 
hypermagnesemia, 
gastrointestinal side 
effect, not well 
studied 
Ferric citrate capsule 176 mg 
elemental 
iron per 1g 
ferric citrate 
   potential for iron 
accumulation, not 
well studied, 
gastrointestinal side 
effects, less effective 
than Ca2+ salts 
SBR759 
(polymeric 
complex of 
starch with 
ferric iron) 
powder 1.25 g per 
sachet  
  powder form potential for iron 
accumulation, not 
well studied  
(1 phase I trial), 
gastrointestinal side 
effects, hypocalcemia 
 
Table 1. Overview of available phosphate binders (adapted from KDOQI, 2003; KDIGO, 
2009; Tonelli et al., 2010; Uhlig et al., 2010). Abbrevations: Ca2+, calcium; HCl, hydrochloride; 
Mg, magnesium; CO3, carbonate; NA, not available. 
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carbonate with calcium carbonate, but found a significantly lower PTH reduction with 
sevelamer hydrochloride in comparison to calcium salts. When all studies were pooled, 
gastrointestinal side effects occurred more often with sevelamer hydrochloride than with 
calcium salts. With the use of sevelamer hydrochloride significantly lower serum 
bicarbonate is found, aggravating already existing metabolic acidosis. The new formula of 
sevelamer carbonate does not negatively influence acid-base status. A possible advantage of 
sevelamer is its significant reduction of LDL-cholesterol. However, no difference in all-cause 
mortality could be found comparing calcium acetate and carbonate, or sevelamer with 
calcium salts. All-cause mortality as endpoint has not been studied with all other phosphate 
binders (Navaneethan et al., 2009).  
Hypercalcemia is a known side effect of calcium salts, especially when combined with 
vitamin D receptor activators. Persistent hypercalcemia necessitates a dose reduction or 
cessation of calcium salts as phosphate binders. The KDOQI guidelines suggest limiting the 
daily calcium intake from calcium-containing phosphate binders to 1500 mg per day for 
elemental calcium and 2000 mg per day for total intake of elemental calcium including the 
dietary calcium content (KDOQI, 2003). Nevertheless, there is no data available to 
recommend a specific upper limit of a safe amount of calcium intake.  Restrictive use of 
calcium-based phosphate binders may be considered in the following situations (Cozzolino 
et al., 2011; Goldsmith et al., 2010): 
 presence of cardiovascular disease 
 presence of vascular or valvular calcification 
 older age (>65 years) 
 diabetes mellitus 
 evidence of adynamic bone disease 
 hypercalcemia 
Although very effective, a prolonged (>3 months continuously, or >6 months cumulative) 
use of aluminium hydroxide should be avoided because of the potential toxicity of 
accumulated aluminium leading to encephalopathy, osteomalacia and anemia (Goldsmith et 
al., 2010). 
Irrespective of the phosphate binder class the successful practical management of 
hyperphosphatemia with phosphate binders includes: 
 concomitant dietary phosphorus restriction (especially phosphorus-rich additives) 
 administration of phosphate binders with the meal 
 individual dosing with respect to eating habits and serum phosphorus level 
A new and promising concept for the management of hyperphosphatemia was recently 
developed to enable patients to self-adjust the phosphate binder dose in relation to the 
phosphorus content of each individual meal: “Phosphate Education Program” (PEP) 
(Ahlenstiel et al., 2010). Patients are taught to eye-estimate the meal phosphorus content 
based on “phosphate units” (PU; 1 PU is defined per 100 mg of phosphorus per serving size 
of the meal) and then phosphate binders are prescribed dependent on an individual 
phosphate binder/PU ratio. This concept is similar to the individualized adjustments of 
insulin dose to carbohydrate intake in the treatment of diabetes mellitus. 
Novel agents under development for the treatment of hyperphosphatemia are MCI-196 
(colestilan) (Locatelli et al., 2010), a non-metallic anion-exchange resin, and niacin and 
nicotinamid, which probably directly inhibit the sodium-dependent phosphate 
cotransporter Na-Pi-2b in the gastrointestinal tract (Muller et al., 2007). 
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2.3 Dialytic methods for phosphorus removal 
Dialytic methods to improve phosphorus removal include prolonged (nocturnal) 
hemodialysis (Culleton et al. 2007; Walsh et al., 2010) and convective strategies (Tonelli et 
al., 2009). 
3. Vitamin D therapy 
3.1 Correction of vitamin D deficiency and insufficiency 
Neither the normal nor the desirable target ranges for 25-hydroxyvitamin D (25(OH)D) 
levels are known in patients on hemodialysis. In accordance with patients without chronic 
kidney disease, 25(OH)D levels <12.5 ng/mL (<30 nmol/L) are defined as vitamin D 
deficiency, values <30 ng/mL (<75 nmol/L) as vitamin D insufficiency. Observational 
studies have shown an association between low 25(OH)D levels and adverse clinical 
outcomes (Holick,  2005; Wolf et al., 2007; Giovannucci, 2008). Although data from clinical 
trials are missing to show a survival benefit after increasing 25(OH)D levels in insufficient or 
deficient hemodialysis patients, current guidelines suggest to replete 25(OH)D stores in 
these patients on grounds of low costs, relative safety of repletion and potential therapeutic 
impact (KDIGO, 2009). After initial measurement and diagnosis of vitamin D deficiency, a 
supplementation using cholecalciferol or ergocalciferol may be initiated with 
remeasurement after 3 months of supplementation. There are no data regarding the choice 
of vitamin D product or the administration route. Altogether, oral repletion seems to be 
more favourable compared to intramuscular route in hemodialysis patients. In accordance 
with the general population a daily dose of 1000 to 2000 IU of cholecalciferol or a 
corresponding weekly dose are given (KDOQI, 2003; KDIGO, 2009; Uhlig et al., 2010). In a 
recent study in 107 hemodialysis patients, 91% of the patients had a serum 25(OH)D level 
higher than the target level of 75 nmol/L (30 ng/mL) after 3 months of monthly oral 
substitution of 100,000 IU (at first dialysis session of the month) (Jean et al., 2009). This 
approach seems to be safe and guarantee patient compliance. If hypercalcemia or 
hyperphosphatemia occurs, vitamin D repletion should be temporarily discontinued or 
abandoned. Table 2 gives an overview of the key differences between 25(OH)D and its 
“active” form 1,25(OH)2D. 
 
 25(OH)D 1,25(OH)2D 
Total plasma concentration  
(recommended  normal values) 
30 to 50 ng/mL 
(75 to 125 nmol/L) 
30 to 50 pg/mL 
(75 to 125 pmol/L) 
Total plasma concentration (relative 
values) 
1000 1 
Binding affinity to vitamin D-binding 
protein (relative values) 
1000 1 
Free concentration (relative values) 1 1 
Half-life 25 to 30 days 4 to 8 hours 
VDR affinity  (relative values) 1 500 to 1000 
 
Table 2. Characteristics and differences of 25(OH)D and 1,25(OH)2D. Abbrevations: VDR, 
vitamin D receptor. 
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3.2 Vitamin D receptor activators 
Treatment of sHPT with active vitamin D receptor activators (VDRA) is a well established 
therapeutic modality, and current practice guidelines recommend to treat patients with 
elevated and/or increasing PTH levels with a VDRA (KDIGO, 2009).  Observational studies 
are indicating a survival benefit of VDRA in hemodialysis patients in comparison with 
patients without VDRA treatment (Teng et al., 2003, 2005; Tentori et al., 2006; Naves-Diaz et 
al., 2008). Again, prospective controlled randomised clinical trials indicating a benefit on 
patient-level clinical outcomes with VDRA therapy are missing but strongly awaited. 
Calcitriol, the physiological VDRA, is the natural regulator of parathyroid gland function and 
growth and exerts its effect on PTH secretion by inhibiting mRNA synthesis through its action 
on the vitamin D receptor (VDR), a highly specific receptor that acts as a transcription factor. 
In addition, calcitriol is able to inhibit PTH secretion by increasing calcium absorption in the 
intestine, while also increasing bone resorption and, consequently, calcium release from bone. 
Moreover, calcitriol regulates the expression of its own receptor, stimulating its synthesis. The 
deficit of calcitriol observed in hemodialysis patients as well as a transformation into nodular 
hyperplasia with progressive sHPT is associated with a decrease in VDR levels in the 
parathyroid gland. Decreased VDR expression may than cause resistance to VDRA. VDRA 
generally control sHPT well in patients with moderately increased hypertrophic glands and 
less well in patients with enlarged hyperplastic glands and should therefore be started early in 
the development of sHPT (Cunningham et al., 2011). Beyond the classical endocrine effects on 
parathyroid gland, bone and intestine, the pleiotropic paracrine and autocrine effects of 
vitamin D have been associated with improvement of cardiovascular risk factors, including 
increased renin activity, hypertension, inflammation, insulin resistance, diabetes, albuminuria 
and an improved immune response.  
Besides the native active hormone calcitriol (1,25(OH)2D3), the two prodrugs alfacalcidol 
(1(OH)D3) and doxercalciferol (1(OH)D2) and the two vitamin D analogues paricalcitol (19-
nor-1,25(OH)2D2) and maxacalcitol (22-oxa-1,25(OH)2D3) can be used. Paricalcitol and 
maxacalcitol (oxacalcitriol) bind directly to the VDR, whereas doxercalciferol and 
alfacalcidol need an enzymatic 25-hydroxylation activation step in the liver. So far no 
prospective, placebo-controlled and blinded clinical trial involving 22-oxacalcitriol, 
paricalcitol, or doxercalciferol has yet demonstrated additional clinical benefits when 
compared with calcitriol, nor have any studies been published showing that either calcitriol 
or alfacalcidol has an advantage over the other with respect to biochemical or clinical end 
points (Cunningham & Zehnder, 2011). Therefore, low dose therapy with calcitriol (e.g. 0.25 
µg/d orally or 0.25 µg thrice weekly orally or intravenously as a starting dose) is 
recommended with elevated or increasing PTH levels (KDIGO, 2009). Characteristics and 
oral calcitriol equivalent doses of various available VDRA are presented in Table 3. 
According to current practice guidelines, the target range for PTH is now 2-9 times the 
upper limit of the normal range (KDIGO, 2009; Uhlig et al., 2010; Goldsmith et al., 2010). 
This wide range takes into account a significant interassay variability of values obtained 
with different commercial PTH assays (Koller et al., 2004; Souberbielle et al., 2010), inability 
to uniformly predict bone histologic and histomorphometric states by means of PTH within 
this range and the epidemiological observation of increased all-cause mortality starting from 
PTH values >400 to 600 pg/mL (Uhlig et al., 2010). If there is no successful response with 
PTH reduction into the suggested target range, or dose-limiting side effects occur, especially 
hypercalcemia and hyperphosphatemia, a calcimimetic can be initiated instead or combined 
with a low dose of VDRA.  
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VDRA Chemical structure 
Oral calcitriol 
equivalent dose 
(thrice weekly) 
Calcitriol 1,25(OH)2D3; natural hormone 
oral 0.25 µg 
intravenous 0.5 µg 
Alfacalcidol 1(OH)D3; synthetic prohormone 
oral 0.5 µg 
intravenous 1 µg 
Doxercalciferol 1(OH)D2, synthetic prohormone 
oral 2.5 µg 
intravenous 5 µg 
Paricalcitol 19nor-1,25(OH)2D2; synthetic analogue 
oral 1 µg 
intravenous 2 µg 
Maxacalcitol 
(Oxacalcitriol) 
22oxa-1,25(OH)2D;3; synthetic analogue NA 
Table 3. Characteristics and oral calcitriol equivalent doses of vitamin D receptor activators 
(VDRA). Abbreviation: NA, not available. 
4. Calcimimetics 
Calcimimetics are allosteric modulators of the calcium sensing receptor that sensitize the 
receptor to extracellular calcium. This results in reduced PTH secretion and inhibited 
parathyroid cell proliferation (Nemeth et al., 1998; Chin et al., 2000). This decrease in serum 
PTH is accompanied by control of serum calcium and phosphorus levels in patients with 
sHPT as well as a halt or regression of parathyroid gland hyperplasia (Meola et al., 2009). 
Initial phase III trials and various observational studies have shown that cinacalcet enables 
more patients to reach the recommended biochemical targets (Block et al., 2004; Lindberg et 
al., 2005; Urena et al., 2009) and allows sustained biochemical control for long term up to 3 
years (Sprague et al., 2009). At present cinacalcet hydrochloride is the only calcimimetic 
available for clinical use. In contrast to VDRA, cinacalcet decreases all three important 
biochemical parameters of CKD-MBD (PTH, phosphorus, calcium) (Urena et al., 2009). In 
addition to excellent results on laboratory parameters, cinacalcet has also shown favourable 
effects on cardiovascular hospitalization, bone fracture rate, parathyroidectomy rate and 
quality of life (Cunningham et al., 2005). In a prospectively designed observational study 
use of cinacalcet on top of standard sHPT therapy with VDRA and phosphate binders 
resulted in a 26% lower all-cause mortality and a 24% lower cardiovascular mortality than in 
patients without cinacalcet, with the largest survival benefit for patients with most severe 
sHPT (PTH >600 pg/mL) (Block et al., 2010). The ongoing double-blind, randomised 
placebo-controlled EVOLVE trial (Evaluation of cinacalcet HCl therapy to lower 
cardiovascular events) currently determines whether cinacalcet reduces all-cause mortality 
or non-fatal cardiovascular events (Chertow et al., 2007). 
Generally, initial therapy starts with a daily dose of 30 mg followed by dose-titration every 2 
to 4 weeks if necessary. Serum calcium levels must be monitored regularly because of its 
known hypocalcemic effect.  
Whereas VDRA reduce PTH gene transcription and hormone synthesis over a period of 
several hours or even days, cinacalcet inhibits PTH secretion within minutes, with a 
maximal decrease occurring within 2 to 4 hours after administration. Besides 
gastrointestinal side effects, hypocalcemia is one of the most common adverse events seen 
with cinacalcet. It is thought to occur after decreased mobilization of calcium from bone 
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caused by lowered PTH levels. In most patients, this hypocalcemia can be successfully 
managed with dose adjustments or a combination with low doses of VDRA in patients with 
moderate to severe sHPT. Clinical trials have demonstrated the superior suppression of 
PTH production and control of calcium and phosphorus in hemodialysis patients who use 
cinacalcet, both as adjunctive therapy to VDRA and as primary therapy with reduced doses 
of VDRA , compared with sHPT therapy  with VDRA and phosphate binders only (Chertow 
et al., 2006; Block et al., 2008; Fishbane et al., 2008; Messa et al., 2008). 
5. Parathyroidectomy 
Persistently increased serum PTH levels >800 pg/mL (88.0 pmol/L) in presence of 
hypercalcemia or hyperphosphatemia refractory to medical therapy and calcific uremic 
arteriolopathy (calciphylaxis) with concomitantly elevated PTH levels are an indication for 
surgery (KDOQI, 2003; KDIGO, 2009). Subtotal and total parathyroidectomy (PTX) with or 
without forearm autograft arose as a treatment option in the 1990s (Tominaga et al., 1997) 
and PTX continues to be a primary therapeutic option for refractory sHPT in both Europe 
and the US. Rates of PTX increased for US patients on hemodialysis from 1998 to 2002 
despite an increase in therapeutic options (Foley et al., 2005). The frequency of PTX across 
Europe has remained relatively stable since the mid-1980s (Malberti et al., 2001) and is lower 
in older patients (Pelletier et al., 2010).   
PTX effectively decreases PTH, calcium and phosphorus and offers the highest percentage 
cure for sHPT, compared to all other medical and surgical treatments. However, recurrent 
hyperparathyroidism can be observed in 10 - 70% of patients dependent on follow-up time 
(Johnson et al., 1988; Gagne et al., 1992; Gasparri et al., 2001).  For total parathyroidectomy 
with autotransplantation an intra-operative selection of parathyroid tissue with diffuse 
hyperplasia but low proliferative potential (and exclusion of nodular tissue) is feasible and 
minimizes the risk of graft-dependent recurrent hyperparathyroidism (Neyer et al., 2002). 
Alternatively to surgery, ultrasound-guided percutaneous fine-needle ethanol injection into 
nodular hyperplastic parathyroid glands is very common in Japan (Giangrande et al., 1992; 
Kitaoka et al., 1994; Fukagawa et al., 1999). Apart from ethanol, also calcitriol or novel 
VDRA can be directly placed into enlarged parathyroid glands using the same technique 
(Shiizaki et al., 2003).  
To date no specific guidelines considering sHPT treatment in hemodialysis patients on 
kidney transplant waiting list have been established. After successful kidney transplantation 
persistent HPT can be observed in up to 25% of patients one year after transplantation 
despite adequate renal graft function. Severity of sHPT at time of transplantation was found 
to be a significant indicator of persistent HPT (Evenepoel et al., 2004).  If indicated, therapy 
for persistent HPT should be initiated about three months after renal transplantation 
because further spontaneous improvement thereafter is rare. Because this special situation 
of persistent HPT after transplantation is usually accompanied by hypercalcemia and 
hypophosphatemia, conventional therapy with phosphate binders, VDRA or calcium 
supplements is not indicated in most patients. Therefore, PTX is the preferred treatment 
option in this situation and has been shown to be effective, safe, though associated with a 
mild deterioration of graft function in the early postoperative phase but similar graft 
survival in the long-term compared to kidney transplant patients without PTX and linked to 
a blood pressure and lipid lowering effect (Triponez et al., 2008). Recently, also cinacalcet 
has been proposed to offer an alternative therapeutic option to PTX, although not approved 
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for the use in this situation and cost-intensive if used for many years (Kruse et al., 2005; 
Serra et al., 2005; Srinivas et al., 2006; Zitt et al., 2007).  
Therefore, we believe that a good and early control of sHPT prior to kidney transplantation 
is mandatory. This should be initially done using all medical options including cinacalcet, 
but if unsuccessful in control of severe sHPT proceeding straight to PTX for an optimal and 
cost-effective treatment. Randomized clinical trials directly comparing medical with surgical 
therapy of sHPT are lacking.   
To avoid severe postoperative hypocalcemia (“hungry bone syndrome), pre-/peri- and 
postoperative calcium and calcitriol supplementation (e.g. 1 to 2 g elemental calcium thrice a 
day, 1 to 4 µg calcitriol per day; parenteral calcium substitution if symptomatic 
hypocalcemia is present with 1 to 2 mg elemental calcium/kg/h) must be guaranteed along 
with frequent controls of serum calcium levels. In case of recurrent or persistent 
hyperparathyroidism after parathyroidectomy, cinacalcet has been shown to be a viable and 
safe treatment option (Zitt et al., 2010).  
6. Dialysate calcium concentration 
A near-neutral calcium flux could be expected in patients with a dialysate calcium 
concentration of 1.25 mmol/L (2.5 mEq/L), although there is considerable interindividual 
variability among patients (Hou et al., 1991; Argiles et al., 1993). Based on calcium kinetic 
modelling even lower dialysate calcium concentrations of 1.0 mmol/L (2.0 mEq/L) might be 
needed to avoid net positive calcium balance (Gotch et al., 2010). The risks of hemodynamic 
instability and cardiac rhythm disturbances with a very low dialysate calcium concentration 
must be kept in mind (Drueke & Touam, 2009). Overall calcium balance is influenced by 
dietary calcium intake, vitamin D level, calcium-containing phosphate binders, use of 
VDRA and calcimimetics and dialysate calcium concentration. Therefore, selecting an 
individual dialysate calcium concentration is based on various parameters and must always 
be a compromise between the need to guarantee cardiovascular stability during the 
hemodialysis session and the goal to maintain normal bone turnover and mineralization in 
order to avoid bone pain and fractures but avoid extraskeletal calcification. 
7. Summary 
Whereas there are insufficient high-quality randomized controlled trials in the field, this 
shortcoming should not lead to a nihilistic approach to the relevant clinical problems of 
hemodialysis patients with sHPT. Nevertheless, because of insufficient clinical data, a single 
treatment modality, be it phosphorus binders, vitamin D substitution with inactive forms or 
vitamin D receptor activators, calcimimetics or parathyroidectomy may not claim to be 
uniformly superior to the others, and a wider therapeutic window often prompts the use of 
a combination of these options and individualization of sHPT management. The ultimate 
goal is to improve the very poor survival of hemodialysis patients, so any suggested 
approach for the management of sHPT should be tested. 
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